Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 43

Drug Profile

IC 43

Alternative Names: IC-43; OprF-OprI vaccine - Valneva; PE-001; PE-002; Pseudomonas aeruginosa vaccine - Valneva; VLA 43

Latest Information Update: 15 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Valneva
  • Class Antibacterials; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 31 Aug 2016 Discontinued - Phase-II/III for Pseudomonal infections (Prevention) in Czech Republic, Spain, Germany, Belgium, Hungary and Austria (IM) because phase II/III trial results did not confirm a positive vaccine effect
  • 21 Mar 2016 Valneva plans a phase III trial for Pseudomonal infections
  • 01 Dec 2015 Valneva completes a phase II/III trial in Pseudomonal infections in Austria, Belgium, Czech Republic, Germany, Hungary and Spain (IM) (NCT01563263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top